Site-specific conjugation technology became a significant trend in ADC drug development; it allows the design of drugs with uniform coupling sites and DAR values, thereby improving pharmacokinetic properties and therapeutic indices 58 .
← all excerpts
Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker.
1
—
—